Business Context and Reporting Period
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company with businesses in Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The filing is an annual Form 20-F for the fiscal year ended March 31, 2021, prepared under IFRS as issued by the IASB and audited by Ernst & Young Associates LLP. The requested “2020 Q4” period is not separately presented; the filing provides annual fiscal-year information.
Financial Performance and Position
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | Rs.189,722 million | Rs.174,600 million | +8.7% |
| Gross profit | Rs.103,077 million | Rs.94,009 million | +9.6% |
| Gross margin | 54.3% | 53.8% | +50 bps |
| Operating profit | Rs.24,280 million | Rs.15,993 million | +51.8% |
| Operating margin | 12.8% | 9.2% | +360 bps |
| Profit before tax | Rs.26,413 million | Rs.18,032 million | +46.5% |
| Profit for the year | Rs.17,238 million | Rs.19,498 million | -11.6% |
| Basic EPS | Rs.103.94 | Rs.117.63 | Declined |
| Net cash from operations | Rs.35,703 million | Rs.29,841 million | +19.6% |
Reported profit declined despite stronger operating and pre-tax results because the prior year included a net tax benefit of Rs.1,466 million, whereas FY2021 included tax expense of Rs.9,175 million, representing an effective tax rate of approximately 35% versus a benefit rate of approximately 8% in FY2020.
- Revenue mix: Global Generics revenue was Rs.154,404 million, up 12%; PSAI revenue was Rs.31,982 million, up 24%; Proprietary Products revenue was Rs.523 million, down 93%; and Others revenue was Rs.2,813 million, up slightly.
- Geography: North America Global Generics revenue increased 9% to Rs.70,494 million; Europe increased 32% to Rs.15,404 million; India increased 15% to Rs.33,419 million; Russia declined 6% to Rs.15,816 million; and Rest of World markets increased 25% to Rs.11,844 million.
- Cash and liquidity: Cash and cash equivalents were Rs.14,829 million, compared with Rs.2,053 million at March 31, 2020. Working capital was Rs.66,626 million, excluding assets held for sale. The company also had uncommitted bank credit lines of Rs.38,766 million.
- Debt: Short-term borrowings were Rs.23,136 million and long-term borrowings were Rs.7,163 million, including lease obligations. Excluding leases, principal debt obligations totaled Rs.26,936 million, of which Rs.23,136 million was due within one year.
- Investing and financing: Investing cash outflow was Rs.22,660 million, including Rs.15,514 million paid for the Wockhardt acquisition and Rs.12,476 million of capital expenditures and other asset purchases. Financing cash outflow was Rs.298 million.
- Dividend: The Board proposed a FY2021 dividend of Rs.25 per share, aggregating to approximately Rs.4,158 million, subject to shareholder approval.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven by higher volumes, new product launches and favorable currency translation, partly offset by price erosion in North America, Europe and emerging markets.
- Gross margin improved primarily from currency benefits, higher-margin launches, product mix and lower growth in manufacturing overheads, despite continuing price erosion and lower export benefits.
- Operating performance improved substantially as impairment charges fell to Rs.8,588 million from Rs.16,767 million. However, FY2021 still included significant impairment of intangible assets.
- Proprietary Products revenue fell sharply because FY2020 included Rs.7,486 million from the sale of U.S. and select territory rights for ZEMBRACE and TOSYMRA.
- PSAI margin increased to 29.5% from 24.0%, while Global Generics margin increased to 59.0% from 56.8%.
- Operating cash flow increased, supported by higher earnings and lower working-capital requirements. Days sales outstanding improved to 93 days from 100 days.
- The company completed its acquisition of selected Wockhardt branded-generics businesses for fair-value consideration of Rs.16,115 million, adding 62 brands, a manufacturing facility and approximately 2,051 employees.
- Capital expenditures increased materially, and capital commitments rose to Rs.9,841 million from Rs.4,888 million.
Guidance, Outlook, Risks and Unusual Items
- Management did not provide a consolidated numerical revenue or earnings guidance in the supplied filing. It expects PSAI growth from investments in newer technologies and platforms and intends to fund expansion primarily through operating cash flow and cash and investments.
- COVID-19 caused marginal delays in clinical trials, regulatory approvals and pre-commercial activities. Management reported no significant operational impact in 2020 but warned that the pandemic, particularly rising infections in India, could disrupt manufacturing, supply chains, approvals, logistics, employee productivity and liquidity.
- On October 22, 2020, the company experienced a ransomware-related cybersecurity incident. It reported timely containment, enterprise-wide remediation and strengthened technical controls.
- On June 14, 2021, after the fiscal year-end, an AAA-ICDR arbitration awarded Hatchtech U.S.$46.25 million relating to Xeglyze. The FY2021 statements were adjusted to recognize the full award, including U.S.$45 million in impairment of non-current assets and U.S.$1.25 million in selling, general and administrative expenses. This was a significant unusual item.
- FY2021 intangible-asset impairment included Rs.3,180 million for gNuvaring, Rs.3,291 million for Xeglyze and Rs.2,071 million for other product-related intangibles. The filing identifies increased competition, price erosion and reduced market potential as key drivers.
- The company remains exposed to U.S. antitrust and pricing litigation, ranitidine-related claims, patent disputes, regulatory investigations, environmental matters and an internal investigation concerning alleged improper payments to healthcare professionals in Ukraine and potentially elsewhere. Many potential liabilities are described as unascertainable and no provision was recorded for several matters.
- Principal business risks include generic price erosion and competition, customer concentration, product quality and regulatory enforcement, patent litigation, supply-chain disruptions, foreign-exchange volatility, tax uncertainty, cybersecurity, COVID-19, environmental compliance and impairment of intangible assets.
Most Important Facts for Investors to Verify
- Confirm the financial impact, settlement status and future commercial prospects of the Hatchtech/Xeglyze arbitration award.
- Review Note 33 contingencies for the potential exposure from U.S. antitrust, ranitidine, pricing, patent and anti-corruption matters, noting that several exposures are not quantified.
- Assess whether the FY2021 operating-margin improvement is sustainable after separating currency effects, lower impairments, new launches and non-recurring items.
- Monitor North America customer concentration, generic price erosion, chargeback accruals and the ability to sustain product volumes.
- Evaluate the integration and returns from the Wockhardt acquisition, including the contingent consideration and acquired intangible assets.
- Review the recoverability assumptions for goodwill and intangible assets, including discount rates, price erosion, market share and product-launch forecasts.
- Verify cash conversion, inventory growth, capital commitments and the refinancing requirements for short-term borrowings.
- Track the ongoing COVID-19 impact, remediation of the ransomware incident and the status of U.S. FDA inspections and quality actions.